MedPath

Effect of Lactobacillus brevis KB290 on bowel movement and on microbiota in subjects with a tendetendency toward constipation: a randomized, double-blind, placebo-controlled, parallel-group trial.

Not Applicable
Conditions
people tend to be constipated
Registration Number
JPRN-UMIN000020990
Lead Sponsor
Kagome Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
130
Inclusion Criteria

Not provided

Exclusion Criteria

People who meet any of the following conditions will be excluded. 1) Who regularly use intestinal drugs and laxatives (including strong laxatives). 2) Who can't stop intake food containing viable bacteria such as Lactic acid bacteria, Bifidobacteria, Natto bacteria and/or enhanced with oligosaccharide, dietary fiber and/or the health food to relieve constipation (including Food for Specified Health Uses (FOSHU)) and/or containing a large amount of sugar alcohol during this study. 3) Who habitually consume higher amount of alcohol (more than 1000 mL in terms of beer per day). 4) Who use medicine such as antibiotics that affect digestion and absorption. 5) Who have allergic to food. 6) Who is pregnant or willing to be pregnant or breast-feeding during this study. 7) Who are participated in other clinical trials that intake/apply any of food, drug, and cosmetics, or willing to be that. 8) Who have serious diseases requiring an urgent treatment, or who accept severe complication. 9) Who has a medical history of diseases or surgeries affecting digestion, absorption and bowel movement (except for appendicectomy). 10) Who has a current or history of drug dependence and/or alcoholism. 11) Who has ever been diagnosed with Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD). 12) Who has an irregular menstrual cycle, or is undergoing treatment for menopause. 13) Who are judged unsuitable for this study based onsubject questionnaire. 14) Who are judged unsuitable for this study by principal investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Defecation frequency and days of defecation per week or 2 weeks will be measured. The changes will be compared within each group and between the treatment groups.
Secondary Outcome Measures
NameTimeMethod
Amount of defecation, Bristol Stool Form Scale, stool color and smell, feeling after defecation will be measured. Also, variety and ratio of bacteria in stool (intestinal microbiota) will be measured. The changes will be compared within each group and between the treatment groups.
© Copyright 2025. All Rights Reserved by MedPath